Hexvix® real world evidence show improved recurrence free survival and health care savings

Photocure ASA is pleased to announce presentations by urology researchers on Hexvix® during the European Association of Urology (EAU) annual meeting held in Munich, Germany 11-15 March 2016. The EAU is one of the largest International meetings in urology, showcasing the latest and most relevant knowledge with more than 12,000 urologists and exhibitors from over 100 countries. Hexvix® is a photosensitizing agent taken up selectively by the tumor cells in the bladder that when exposed to blue light during a cystoscopic procedure results in a bright pink fluorescence of the suspicious tissue. Using Hexvix® as an adjunct to standard white light cystoscopy enables the urologist to better detect and remove lesions, leading to a reduced risk of recurrence.

Dr. Kjetil Hestdal, President  & CEO of Photocure ASA comments: "We are delighted to see the expanding body of evidence supporting Hexvix® and its role in the detection and management of bladder cancer.  Real world data now demonstrates the clinical and health economic benefits of Hexvix® in a day-to-day clinic setting supporting its widespread use. As more urologists are exposed to the continued flow of data with Hexvix®, more patients will have access to its substantive benefits."

The Hexvix® evidence from theory with its unique mode of action, randomized clinical trials, and real world evidence were presented by Professor Dr. Maximillian Burger, Chair of Urology of the University of Regensburg during a symposium "Moving Forward in Urological Cancers" sponsored by Ipsen Uro-oncology, strategic commercialization partner for Hexvix® in Europe, excluding the Nordic region.    

Burger highlighted that bladder cancer is often under recognized and undertreated.  Despite the large majority of the audience voting that they follow the guidelines he stated that there is still room for improvement.  He concluded that "Hexvix® has been proven to offer significant benefits in the detection and reduction in recurrence rates and emerging real world evidence now confirms these findings, and even indicates better patient outcomes- especially in high risk non-muscle invasive bladder cancer (NMIBC) patients, where it matters most.  The strong real world data can give us even more confidence managing patients in our daily clinical practice.  It improves recurrence free survival and there are significant savings to the health care system as every third follow up TURB can be avoided."

Hexvix® is recommended for use in the diagnosis and management of NMIBC patients in the EAU guidelines, NICE guidelines as well as a number of country specific guidelines across Europe. The EAU guidelines for the management of non-muscle invasive bladder cancer (NMIBC) have been developed after thorough assessment of all clinical, safety and outcomes evidence to provide recommendations on the best practice for managing these patients, from diagnosis through treatment.  

However, there is currently considerable variability across Europe with adherence to EAU guidelines, as reported in a poster presentation by Dr. E. N. Xylinas, Cochin Hospital, Paris Descartes University. "Improved adherence to the EAU guidelines on the management of patients with NMIBC would ensure all patients across Europe have access and may benefit from the optimal methods for detecting and managing the disease like Hexvix® Blue-Light cystoscopy" concludes Dr. Xylinas.  

For further information, please contact:

Kjetil Hestdal
President and CEO
Photocure ASA
Tel. +47 913 19 535